Patients with stage II/III rectal cancers are treated with neoadjuvant chemoradiation and surgical resection followed by adjuvant chemotherapy (CT) per practice guidelines. It is unclear whether adjuvant CT provides survival benefit, and the purpose of this study was to measure outcomes in patients who did and did not receive adjuvant CT.
C olorectal cancer is one of the most common malignancies in the world. In 2011, approximately 39,870 new cases of rectal cancer were diagnosed in the United States, with a significant proportion having locally advanced disease. 1 In patients with locally advanced rectal cancer, a surgical approach with a total mesorectal excision is the treatment of choice. To improve the rate of margin-negative resection, sphincter preservation, and to decrease the rate of local recurrence and prolong overall survival (OS), patients with locally advanced, clinically resectable (T3/T4 and/or positive nodal status) rectal cancer are recommended to receive concurrent chemoradiation (CRT). Studies have shown that neoadjuvant CRT significantly increased local control with decreased rates of local recurrence compared with postoperative chemoradiation or preoperative radiotherapy alone. Long-term follow-up did not show any survival differences in patients who received neoadjuvant versus adjuvant chemoradiation therapy. [2] [3] [4] However, there is uncertainty as to whether adjuvant chemotherapy (CT) provides any additional benefit in patients who have previously received neoadjuvant CRT. Clinical trials that have attempted to address this inquiry have left clinicians with a lack of clarity. Several clinical trials suggested a lack of benefit for adjuvant CT following neoadjuvant chemoradiation and surgery in resectable rectal cancer. These studies had significant limitations that complicate interpretation including the inconsistent use of neoadjuvant chemoradiation (PROCTOR/SCRIPT), poor adherence (EORTC 22921), lack of optimal dosing, and/or prolonged postoperative complications. 3, [5] [6] [7] [8] [9] However, based on adjuvant CT recommendations extrapolated from stage III colon cancer data, current NCCN guidelines suggest patients with rectal tumors staged as a T3 or N1 and higher are to consider adjuvant fluoropyrimidine-based CT (either 5-FU or capecitabine) with or without oxaliplatin following neoadjuvant CRT and surgery. [10] [11] [12] [13] [14] To assess the efficacy and outcomes of adjuvant CT following neoadjuvant therapy and surgery in rectal cancer, we conducted a study utilizing a prospectively maintained database in predefined patients with stage II or III rectal cancer who received neoadjuvant chemoradiation followed by surgical resection and subsequent adjuvant CT at the Ohio State University Comprehensive Cancer Center. (1) sufficient patient data were available for patients diagnosed in 2005; and (2) the 2011 cutoff allowed for sufficient follow-up at the time of outcome analysis. Using these data, we analyzed OS, time to recurrence (TTR), patient characteristics, tumor features, and treatments. OS was determined from the date of initial diagnosis to death of any cause. Patients who were still alive were censored at the date of last follow-up. TTR was calculated from the date of initial diagnosis to disease recurrence. Patients who were still disease free were censored at the date of last disease-free follow-up. Survival curves were estimated using Kaplan-Meier method and compared by the logrank test. Age was compared using the Wilcoxon test and other categorical variables were compared using the w 2 test or the Fisher exact test. Duration of adjuvant CT was compared among the different types of adjuvant CT (1 drug vs. 2 drugs vs. unknown) using Kruskal-Wallis test. Multivariate Cox regression hazard models were used to adjust for patient characteristics and estimate hazard ratios with 95% CI for OS and TTR. A P-value <0.05 was considered as statistically significant.
MATERIALS AND METHODS

RESULTS
We identified 110 patients with stage II or III rectal cancer who were treated with neoadjuvant CRT between August 1, 2005 and July 31, 2011. Baseline patient and tumor characteristics are shown in Table 1 . Of the 110 patients who were eligible to receive adjuvant CT, 39 patients (35%) did not receive adjuvant CT (Table 2 ). Of those, 29 (75%) did not receive adjuvant therapy due to physician discretion for reasons other than performance status, surgical complications, or comorbidities, 4 (10%) due to postoperative complications, 4 (10%) due to patient choice, and 2 patients (5%) developed metastatic disease shortly after resection (Table 2) .
There were no significant differences in sex, race, pathologic tumor stage, downstaging after neoadjuvant chemoradiation, or complete pathologic response between patients who received adjuvant CT versus those who did not. However, patients who received adjuvant CT were younger with a median age of 54.3 years, in comparison with a median age of 62 years (P = 0.01) in patients who did not receive adjuvant treatment. Conversely, patients who were treated with adjuvant CT were less likely to achieve a pathologic complete response (10% vs. 21%, P = 0.12). These patients had more advanced pathologic nodal stage compared with patients who did not Transanal excision 4 (10) 6 (8) receive adjuvant therapy (43% vs. 19%, P = 0.02). All patients received a total mesorectal excision, the standard of care at our institution, with similar surgical procedures between patients who did or did not receive adjuvant CT, as shown in Table 3 . Overall, in patients who received adjuvant CT, the median duration of treatment was 3.5 months (range, 2 to 6 mo). Adjuvant CT regimen was based on physician choice, with 38 patients who received single-agent fluoropyrimidine (5-FU or capecitabine) and 33 patients received FOLFOX. In patients who received adjuvant CT, the median OS was 72.6 months compared with 36.4 months in patients who underwent observation ( Fig. 1, OS ; P = 0.0003). At the time of analysis, the median TTR was not reached. However, adjuvant CT had a trend toward an improvement in the median TTR (Fig. 2,  TTR) . Using a multivariate Cox regression model, and after adjusting for treatment, pathologic N status, and age, advantages in median OS and time to first recurrence in the adjuvant CT arm remained significantly improved in the adjuvant CT group (Table 4) .
DISCUSSION
Despite the lack of evidence from randomized clinical trials supporting the use of adjuvant CT in rectal cancer following neoadjuvant CRT and surgical resection, it has become the de facto integrated strategy based on practice guidelines. The rationale for adjuvant therapy has been mostly based on data extrapolated from colon cancer trials in addition to the described patterns of recurrence seen in resected rectal cancer. A number of studies, including a recent Cochrane review, showed a 17% risk reduction in death and a 25% risk reduction in disease recurrence among rectal cancer patients who received neoadjuvant CRT and surgical resection followed by adjuvant CT compared with those who did not receive adjuvant CT. [15] [16] [17] Other studies that investigated the use of adjuvant CT following neoadjuvant CRT and surgical resection (PROCTOR/SCRIPT, EORTC 22921) yielded negative results. In contrast, in our study, patients with resected rectal cancer following neoadjuvant CRT who received adjuvant CT were found to have a significant survival benefit and time to first recurrence over those who did not receive adjuvant therapy. Most recently, a number of studies presented at ASCO 2014 (ADORE, CAO/ARO/AIO-04) support the results of our findings by suggesting an improved clinical outcome in rectal cancer patients with advanced disease (stage II/III) who received neoadjuvant chemoradiation and surgery followed by adjuvant FOLFOX CT. 9, 18 In our study, patients who received CT were younger but had more advanced nodal disease involvement, an adverse prognostic factor. Among patients who did not receive adjuvant CT, 29 did not based on physician choice. Most commonly stated reasons for this choice were the absence of data that supported adjuvant treatment in this setting, less adverse prognostic factors such as less advanced disease, and less occasionally older age. Interestingly, the OS benefit advantage persisted in a multivariable model after controlling for the baseline characteristics of age and nodal status.
Principle limitations to interpreting the results of our study include its retrospective nature, although the data were analyzed from a prospectively collected database, its limited sample size, and the fact that this is a single-center setting that may cause a selection bias. Among the parameters we examined, we did not take into account tumor location, which could have created an imbalance and effected outcomes between the patients who did and did not receive CT. Moreover, of the 39 patients who did not receive adjuvant CT, we reported documented reasons as to why they did not receive adjuvant treatment; however, there might have been an unforeseen and unaccounted bias in the selection of patients who received adjuvant CT.
In conclusion, based on our findings and those from most recent studies, for patients with stage II/III rectal cancers who are treated with neoadjuvant chemoradiation and surgical resection, strong consideration should be given to adjuvant CT. Although there seems to be a significant benefit in OS, further refinement is needed to determine the (clinical or molecular) subset of patients that is most likely to benefit from CT. It is also essential to determine the optimal duration and intensity of the adjuvant CT regimen. Finally, integrating novel-targeted therapies such as immunotherapies (eg, PDL-1) should be of prime interest. 
